NovoMedix’s clinical candidates have novel biological response profiles
NovoMedix discovers and develops proprietary small molecules that target
key regulatory pathways in incurable diseases. Our initial focus is metastatic triple negative
breast cancer (mTNBC) and treatment of cardiopulmonary injuries.
mTNBC is considered incurable with a median survival of 8-13 months. These first-in-class drug candidates effectively treat primary and metastatic TNBC alone or in combination with other cancer drugs (including checkpoint inhibitors) in animal models by blocking the pro-survival and immune suppressive effects of the tumor microenvironment that drive cancer progression. In addition, NM drugs reduce chemotherapy-induced cardiotoxicity and thereby improve survival and long term outcomes for TNBC patients.
The leading cause of mortality in acute respiratory infections, such as severe COVID-19, is complications from Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS) resulting in respiratory and/or heart failure. Patients with underlying health conditions (asthma, COPD, obesity, diabetes, heart disease) are at higher risk than others. Further, patients who recover from severe respiratory infections may have damaged lungs and hearts with subclinical persistent injury, which could progress to fibrosis, resulting in long-term adverse outcomes that may require lung and/or heart transplant. NovoMedix clinical candidates have been shown to reduce inflammation and fibrosis in several different animal models of lung and heart injury. These drugs could be used to treat ALI/ARDS and decrease mortality in COVID-19 patients and in future respiratory infections.
April 26, 2020
Late Breaking Research titled: "Synergistic anti-metastatic effect of pembrolizumab in combination with a novel mTORC1 inhibitor/AMPK agonist in a CAM metastatic triple negative breast cancer model" to be presented as an E-Poster (Tumor Biology 2, Abstract# 10226) at the Virtual AACR 2020 Annual Meeting. Abstract will be published May 15. E-Poster available for browsing June 22. For a copy of the poster, please email firstname.lastname@example.org after June 22, 2020.
September 18, 2019
NovoMedix is the recipient of an Phase I SBIR Grant funded by the National Heart, Lung, And Blood Institute of the National Institutes of Health (award Number R43HL147726) titled: Novel small molecules for protection against doxorubicin cardiotoxicity in TNBC.
August 26, 2019
The abstract titled “Novel Dual MTOR Inhibitors/AMPK Activators Attenuate Doxorubicin-induced Cardiotoxicity” has been accepted for a Rapid Fire Oral Presentation in American Heart Association Scientific Sessions on November 17, 2019.
August 12, 2018
Publication in American Journal of Physiology Heart and Circulatory Physiology Titled "A novel fibroblast activation inhibitor attenuates left ventricular remodeling and preserves cardiac function in heart failure” highlights NovoMedix’s novel antifibrotic therapeutics program in cardiovascular injury.